

L-ARGININE, BUT NOT L-NAME PROTECTS AGAINST LIVER INJURY INDUCED BY EXPERIMENTAL ISCHEMIA-REPERFUSION

O. M. Oleshchuk, K. A. Posokhova, A. Ye. Mudra

I. YA. HORBACHEVSKY TERNOPIL STATE MEDICAL UNIVERSITY, TERNOPIL, UKRAINE

Background. Hepatic ischemia-reperfusion (I/R) injury occurs upon restoration of hepatic blood flow after a period of ischemia.

Objective. The study establishes that stimulation or blockade of nitric oxide synthesis has a protective effect during ischemia-reperfusion.

Methods. Male albino rats which were divided into four equal groups: sham-operated control, ischemia and reperfusion group (0.9 % saline i.p.) for 3 days, group pre-treated with L-arginine (25 mg/kg i.p.), group pre-treated with L-NAME (10 mg/kg i.p.) for 3 days before ischemia-reperfusion maneuver. Complete ischemia of the median and left hepatic lobes was induced by clamping the left branches of the portal vein and the hepatic artery for 45 min. Rats were sacrificed after 3-h reperfusion. Nitric oxide synthase 3 (endothelial) and nitric oxide synthase 2 (inducible) expression, nitric oxide stable metabolites (NO_2 , NO_3) content, AST and ALT activities were determined. Histological examination of liver tissue was performed.

Conclusions. Relative NO deficiency, due to eNOS inhibition, is central in the pathogenesis of hepatic ischemia reperfusion injury. Replacing NO content with either precursors or via donor drugs represents novel methods in ameliorating ischemia-reperfusion injury.

KEY WORDS: hepatic ischemia-reperfusion, nitric oxide, NOS isoforms, L-arginine, L-NAME.

Introduction

Ischemia-reperfusion (I/R) of the liver is a complex of pathophysiological processes that occurs during surgery, trauma, liver transplantation and can lead to serious liver injury. Basic mechanisms of liver IR are not completely understood at present time, but we claim that reactive oxygen and nitrogen are important in this process. Overproduction of free radicals by activated Kupffer cells and neutrophils causes a number of toxic effects, including changes in lipid and protein oxidation, excretion of proinflammatory mediators and microvascular dysfunction, which together lead to cell and tissue damage [1]. According to Bahde H. (2010), the hepatic microcirculation violations and endothelial dysfunction also play main role in the pathophysiology of I/R at the time of reperfusion [2]. The biologically active molecule of nitric oxide (NO) may play a pivotal role in the process of free radicals formation.

However, the data about the protective or damaging role of NO during I/R are controversial. According to some studies the application of NO precursors minimizes the adverse effects of reperfusion and improves hepatic microcirculation [3,4]. On the other hand, studies of some researchers

suggest that inhibitors of NO synthesis can prevent liver damage during I/R [5].

This study shows that stimulation or blockade of nitric oxide synthesis has a protective effect during ischemia-reperfusion.

Methods

NO precursor – L-arginine and non-selective NOS blocker – L-NAME (N-nitro-L-arginine methyl ester) were procured from Sigma; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) kits were procured from “Filisit–diagnostic”, while TNF- α , IL-1 β , IL-6, eNOS, and iNOS ELISA kits were procured USCN Limited Inc.

Animal model

Male white rats (Ternopil State Medical University vivarium, Ukraine) 8 to 10 weeks old, were used for these experiments. All animals were fasted 12 h before experimentation and allowed water *ad libitum*. All animals received care in compliance with the “Guide for the Care and Use of Laboratory Animals” (National Institute of Health Publication № 85-23, revised 1985). The studies were carried out according to the National Institute of Health Guide for the Care and Use of Laboratory Animals and were approved by the local animal protection committee.

Induction of ischemic and reperfusion injury

The hepatic ischemia-reperfusion (I/R) protocols were performed as described in a previous study by Oleshchuk, 2012 [6]. There was no mortality

Address for correspondence: Oleshchuk O.M., m. Voli, 1, Ternopil, 46001, Ukraine
Tel.: +380 352523987.

observed associated with this model. The liver of each rat was exposed through a midline laparotomy after the induction of anesthesia (thiopental sodium 20 mg/kg i.p.). Complete ischemia of the median and left hepatic lobes was induced by clamping the left branches of the portal vein and the hepatic artery for 45 min. The right hepatic lobe was perfused to prevent intestinal congestion. After the time frame sufficient for ischemia development, the ligatures around the left branches of the portal vein and hepatic artery were removed. In order to accurately evaluate the blood flow in the median and left hepatic lobes after ischemia, the right branches of the portal vein and the hepatic artery were ligated to prevent shunting to the right lobe after reperfusion and perfused for 2 h. The wound was stitched with 3.0 silk suture. Sham-operated animals were similarly prepared except that no ligature was placed to obstruct the blood flow to the left and median hepatic lobes. Instead, the blood flow to the right lobe of the liver was occluded. Rats were sacrificed in all groups after 1-h ischemia followed by 3-h reperfusion. Twenty four white rats were divided into four equal groups (n=6 each group). Group 1 (sham-operated control group) and group 2 (ischemia and reperfusion group) were given 0.9% saline (1 mL/kg, i.p.) for 3 days. Group 3 was pre-treated with L-arginine (25 mg/kg i.p.), group 4 – with L-NAME (10 mg/kg i.p.) for 3 days before, (last time – 10 min before) induced ischemia-reperfusion maneuver.

Peripheral blood and hepatic tissue procurement

Blood sampling for determination of liver enzymes. Blood samples were obtained from the right ventricle via left anterior thoracotomy at the time of sacrifice. Blood was collected in a sterile syringe without anticoagulant and centrifuged at 2000 g to separate the serum. The serum samples were stored at -20 °C until use for AST and ALT assays.

Blood sampling for cytokine and NOS determination. Serum was removed from blood samples by clotting for 2 hours on ice; serum was centrifuged at 2,500×g (4 °C), filtered, aliquoted, and frozen at -20 °C until assayed for eNOS and iNOS. Small liver samples were collected from each rat, then frozen immediately and stored in liquid nitrogen until used for eNOS and iNOS assays.

Determination of liver enzymes function

Determination of AST (EC 2.6.1.1) and ALT (EC 2.6.1.2) in plasma was performed by Raytman-Frenkel method, using a standard kit "Filisit-diagnostic" (Ukraine) according to the manufacturer's instructions. The activity of AST and ALT in serum were expressed in mmol/(L×h).

NO₂ and NO₃ assays.

NO₂ and NO₃ in serum of blood and liver homogenates (1:10) were determined as described by several authors [7].

NOS assays

Determination of eNOS activity was performed by ELISA method using "Enzyme-linked Immunosorbent Assay Kit for Rat Nitric Oxide Synthase 3, Endothelial (NOS3)", USCN, Life Science Inc, E90868Ra.

Determination of iNOS activity was done by ELISA method using "Enzyme-linked Immunosorbent Assay Kit for Rat Nitric Oxide Synthase 2, Inducible (NOS2)", USCN, Life Science Inc, E90837Ra.

eNOS and iNOS expression was investigated in blood plasma and liver tissue. Blood was collected using EDTA as an anticoagulant. Samples were centrifuged for 15 min at 1000 g/min at 2–8 °C within 30 min after collection. Determination was carried out immediately or frozen at -20 °C.

The procedure of liver cells lysis was performed as follows:

1. Preparing liver homogenates in isotonic NaCl solution at a ratio of 1:10.
2. Liver cells were centrifuged for 5 min at 300 g, and then the supernatant was removed.
3. Cells were washed twice with isotonic NaCl solution, after each wash the suspension was centrifuged at 300 g for 5 min.
4. Buffer (PBS) was added to the normal liver tissue lysate (1 ml of buffer at 1×10⁶ liver cells). It was centrifuged for 5 min at 300 g.
5. The supernatant was collected. Determination of enzyme activity was carried out immediately or the supernatant was frozen at -20 °C.

Determination of eNOS and iNOS concentration were performed by ELISA method and according to the manufacturer's instruction. eNOS activity in serum and in hepatocytes (1 ml – 1×10⁶ cells) was expressed as U/ml, and iNOS activity was expressed as ng/ml.

Histopathology study

A portion of the tissue from the ischemic liver lobe was fixed in 10 % neutral-buffered formalin solution for 5 days, embedded in paraffin, and sectioned. The sections were stained with hematoxylin and eosin.

Statistical analysis

Statistical analysis was carried out by OriginPro Program. Results are expressed as mean±standard deviation. Differences between experimental groups were analyzed with an unpaired 2-tailed Student *t* test. All differences were considered statistically significant at a p<0.05.

Results

The results indicate that after 45 min post-ischemia followed by 2 h reperfusion the activity of ALT in blood increased from (0.44±0.10) in the sham control group compared to (2.35±0.09) in I/R group

animals, which is 5.3 times increase. Accordingly, AST activity increased from (1.63±0.12) to (4.27±0.37), which is 2.6 times increase. The described dynamics indicates that cytolysis process of hepatocytes is evolving under simulated IR injury (Table 1).

The significant increase in ALT and AST activities, that occurred in I/R group, was significantly suppressed by pre-treatment with 25 mg/kg L-arginine (Table 1). Thus, the transaminases activity was significantly lower: ALT (53.2 %) and AST (33.6 %). The activity of ALT and AST increased by 38 % and 84 % with the introduction of L-NAME compared to those of animals with the I/R alone. The activity of these enzymes was different from the control values by 7.4 and 4.8 times, respectively. This highlights a further progression of cytolysis and output of enzymes from the damaged hepatic tissue as a result of L-NAME pre-treatment.

Therefore, it was found that stimulation of NO synthesis in the animals with I/R improved function of the liver and blockage of NO synthesis by nonselective NOS inhibitor L-NAME aggravates liver injury.

Stimulated iNOS activity was registered in I/R treatment, content of which in the liver increased by 57.6 %, while in the serum – by 185.0 %. Whereas, the concentration of eNOS in the liver was reduced by 38.5 % and in the blood by 18.2 % compared with the group 1 (Table 2).

These changes took place on the background of a decline in serum levels of stable metabolite of nitric oxide NO₂⁻ by 51.7 %. This value has not changed significantly in the liver relative to the control group of similar animals. The level of NO₃⁻ in the blood did not change significantly compared to the liver where it was reduced by 65.5 % (Table 3). Quantitative indicators can be evaluated as a manifestation of a decrease in the total content of final metabolites of NO in both blood and liver during I/R trial.

The intensity of metabolism of nitric oxide under conditions of prophylactic administration of its precursor was evaluated by the concentration of its stable metabolites (Table 3) and the activity of NO-synthase isoforms (Table 2).

The level of nitric oxide metabolites in the blood increased: NO₂⁻ – by 3.7 times, and NO₃⁻ – by 31.7 %, respectively, after administration of L-arginine, and in liver homogenates the content of nitrite anion was not changed (p>0.05), and the nitrate anion increased respectively by 3.1 times.

We observed one-way influence of the substance on the expression of NO-synthase isoforms, both in blood and in the liver. Enzyme immunoassay results showed that the use of L-arginine in I/R treatment leads to increased eNOS content in hepatocytes (43.5 %) and the reduction of iNOS (19.2 %) (Table 2). A similar pattern was observed

Table 1. Effect of L-arginine on ALT and AST activity in the liver of sham and experimental groups of rats

Data	Sham (group 1)	I/R injury (group 2)	L-arginine +I/R (group 3)	L-NAME+I/R (group 4)
ALT	0.44±0.10	2.35±0.09 p<0.001	1.10±0.09 p<0.005 p ₁ <0.001	3.25±0.12 p<0.001 p ₁ <0.001
AST	1.63±0.12	4.27±0.37 p<0.001	2.83±0.20 p<0.01 p ₁ <0.05	7.87±0.15 p<0.001 p ₁ <0.001

Results are expressed as mean±SD (n=6); significantly different: p – from sham, p₁ – from I/R injury group; activity of ALT and AST are expressed in mmol/(l·h)

Table 2. eNOS and iNOS content in liver and blood of sham and experimental groups

Groups	Blood		Liver	
	eNOS U/ml	iNOS ng/ml	eNOS U/ml (1 ml – 1×10 ⁶ cells)	iNOS ng/ml (1 ml – 1×10 ⁶ cells)
Sham (group 1)	3.18±0.17	24.95±0.97	7.95±0.60	2.68±0.16
I/R (group 2)	2.60±0.14 p<0.05	71.22±4.01 p<0.001	4.86±0.24 p<0.001	4.22±0.16 p<0.001
L-arginine+I/R (group 3)	3.50±0.24 p>0.1 p ₁ <0.05	53.54±1.74 p<0.001 p ₁ <0.001	6.98±0.17 p>0.1 p ₁ <0.001	3.41±0.14 p<0.05 p ₁ <0.001
L-NAME+I/R (group 4)	1.14±0.12 p<0.001 p ₁ <0.001	31.40±1.61 p<0.001 p ₁ <0.001	2.99±0.20 p<0.001 p ₁ <0.001	2.56±0.06 p>0.1 p ₁ <0.001

For this and for the following table the results are expressed as mean±SD (n=6); significantly different: p – from sham, p₁ – from I/R injury group

Table 3. NO₂⁻ and NO₃⁻ content in liver and blood of sham and experimental groups

Groups	Blood		Liver	
	NO ₂ ⁻ , micromol/l	NO ₃ ⁻ , micromol/l	NO ₂ ⁻ , micromol /kg	NO ₃ ⁻ , micromol /kg
Sham (group 1)	1.62±0.08	10.18±0.41	1.70±0.11	9.29±0.59
I/R (group 2)	0.78±0.05 p<0.001	9.90±0.46 p>0.05	1.67±0.16 p>0.05	3.20±0.77 p<0.001
L-arginine+I/R (group 3)	2.84±0.07 p<0.001 p ₁ <0.001	13.05±0.63 p<0.01 p ₁ <0.01	2.07±0.10 p>0.05 p ₁ >0.05	9.94±0.60 p>0.05 p ₁ <0.001
L-NAME+I/R (group 4)	0.43±0.04 p<0.001 p ₁ <0.01	8.65±0.12 p<0.05 p ₁ <0.05	0.98±0.03 p<0.001 p ₁ <0.05	1.73±0.07 p<0.05 p ₁ >0.05

in blood. Inducible NO-synthase was reduced by 24.8 % after the use of L-arginine, but remained higher by more than 2.1 times, compared with sham group of animals. Endothelial isoform of the enzyme increased by 34.5 % compared to its value in group 1. To summarize, we can say that prophylactic administration of NO precursor L-arginine before I/R was followed by the activation of a constitutive NO-synthase, with a simultaneous decrease of inducible NOS activity and increase in nitric oxide metabolites level.

It is logical that the expression of both isoforms of nitric oxide synthase, on the background of inhibition of L-NAME, decreased eNOS content was even lower than in the group of animals without correction by 56.5 and 38.5%, and the expression of iNOS decreased by 55.9 and 39.3 % in blood and hepatocytes.

Therefore, L-NAME reduced expression of all NOS forms (Table 2). It was also shown that the level of nitrite and nitrate anions after administration of non-selective blocker of NO synthesis decreased by 45.0 and 12.6% in the serum and by 41.1 and 46.0 % in liver homogenates compared to IR. The levels were also significantly lower in the affected organ (by 1.7 and 1.8 times) compared to the group

of animals. We can hypothesize that reduction of end metabolites of nitric oxide synthesis correlates with inhibition of NO synthase expression in both serum and liver (Table 3).

During histological examination of liver tissue of animals, which previously were administered L-arginine and subsequently simulated ischemia-reperfusion, we found that the trabecular structure of the liver lobules was preserved. The central veins were dilated and well visualized. Periportal areas had lymphocytic and histiocytic infiltration, particularly around the bile duct (Fig. 1).

Histological examination of liver tissue in ischemia-reperfusion model on the background of the previous L-NAME administration showed that the trabecular structure of the liver lobules was significantly changed (Fig. 2).

Sinusoids were greatly expanded and they were free from red blood cells in central lobular areas. Narrowed and saturated cell macrophages in the central and peripheral parts of the liver lobules were not present as well. Portal tracts expanded mainly due to the plethora of vessels and severe peri-vascular lymphocytic and histiocytic infiltration. Signs of small droplets of fat and protein degeneration were present. Enhanced bile ducts and the presence of a




Fig. 1. Histological structure of the liver after administration of L-arginine in ischemia-reperfusion injury. Hematoxylin-eosin. Magnification power 160x.




Fig. 2 Histological structure of the liver during ischemia-reperfusion and application of L-NAME. Hematoxylin-eosin. Magnification power 160x.

small amount of bile can be estimated as intrahepatic cholestasis. A large number of cells with pyknotic nuclei and necrotic cells were observed during histological observation in periportal zone of acinus.

Discussion

I/R is a series of multifaceted cellular events which take place on the resumption of oxygen delivery to the affected organ after a period of hypoxia. IR occurs in the liver during procedures that are associated with vascular inflow obstruction followed by restoration of blood flow. I/R may result in major hepatocellular damage [8].

NO plays a significant role in the acute phase of I/R, as this phase is associated with a rapid decrease in available NO. This decrease occurs either by depressed production by eNOS in sinusoidal endothelial cells, increased degradation by reactive oxygen species, or both [9]. In this I/R study expression of liver iNOS increased and eNOS level decreased. It was determined during our previous I/R studies that the levels of IL-1 β , IL-6 and TNF- α in I/R were significantly increased [6]. Therefore, cytokines provoked stimulation of iNOS expression. To summarize, there is a lack of synthesis of NO during the early periods of reperfusion, which may be due to inhibition of eNOS [9]. As for this study, we have found that after 2 hours of reperfusion levels of nitrates do not change significantly in the blood with decrease in the liver, and conversely decreased blood nitrite levels.

We have shown that the application of L-arginine during I/R trial causes activation of nitric

oxide synthesis. Increased concentrations of NO stable metabolites nitrite and nitrate anions in both blood and liver is consistent with our previous results and other scientific data [10, 11]. We observed one-way impact on the content of NO-synthase isoform in blood and in the liver. The level of endothelial form increased and inducible – declined. Results of our histological studies have shown that the precursor of nitric oxide synthesis has protective influence on the morphological structure of hepatocytes.

Blocking the enzymatic synthesis of NO in liver I/R led to the aggravation of the pathological process, as evidenced by the results of our biochemical and histological studies.

Thus, the introduction of non-selective blocker of NOS-L-NAME increased activity of ALT and AST, indicating a further increase cytolysis of hepatocytes and this is consistent with L. M. Wang et al. (2003) [12]. Our results on the liver degradation by complete blocking enzymatic NO formation during I/R suggest NO protective role during early reperfusion.

Conclusion.

Ischemia reperfusion injury is a well-defined threat to the liver during periods of interruption and restoration of oxygen delivery. It occurs in certain procedures such as hepatic resections and orthotopic liver transplantation. Relative NO deficiency, due to eNOS inhibition, is central in the pathogenesis of this injury. Replacing NO per se either precursors or via donor drugs represents a novel method for ameliorating hepatic ischemia-reperfusion injury.

References

1. Selzner N, Rudiger H, Graf R, Clavien P. Protective strategies against ischemic injury of the liver. *Gastroenterol* 2003; 125: 917–936.
2. Bahde H, Spiegel HU. Hepatic ischemia-reperfusion injury from bench to bedside. *Bri J Surg* 2010; 97: 1461–1475.
3. Ohmori H, Dhar D, Nakashima Y et al. Beneficial effects of FK409, a novel nitric oxide donor on reperfusion injury of rat liver. *Transplantation* 1998; 66: 579–585.
4. Shah V, Kamath SP. Nitric oxide in liver transplantation: pathobiology and clinical implication. *Liver Transplantation* 2003; 1 (9): 1–11.
5. Lin HI, Wang D, Leu F-J. et al. Ischemia and reperfusion of liver induces eNOS and iNOS expression: effects of NO donor and NOS inhibitor. *Chin J Physiol* 2004; 47 (3): 121–127.
6. Oleshchuk OM. Experimental study of nitric oxide precursors in hepatic ischemia-reperfusion. *Hospital surgery* 2012; 4(60): 42–47. (in Ukrainian)
7. Kiselyk IO, Lutsyk MD, Shevchenko LY. Features determination of nitrate and nitrite in the blood of patients with viral hepatitis and jaundice of different etiology. *Lab diagnostyka* 2001; 3: 43–45. (in Ukrainian)
8. Phillips L, Lopez-Neblina F, Toledo-Pereyra LH. Nitric oxide mechanism of protection in ischemia and reperfusion injury *J Invest Sur* 2009; 22: 46–55.
9. Hines IN, Kawachi S, Harada H et al. Role of nitric oxide in liver ischemia and reperfusion injury. *Mol Cell Biochem* 2002; 234/235: 229–237.
10. Chattopadhyay P, Shukla G, Wahi AK. Protective effect of L-arginine against necrosis and apoptosis induced by experimental ischemic and reperfusion in rat liver. *Saudi J Gastroenterol* 2009; 15 (3): 156–162.
11. Chander V, Chopra K. Renal protective effect of molsidomine and L-arginine in ischemia-reperfusion induced injury in rats. *J Surg Res* 2005; 128: 132–139.
12. Wang LM, Tian XF, Song QY et al. Expression and role of inducible nitric oxide synthase in ischemia-reperfusion liver in rats. *Hepatobiliary Pancreat Dis Int* 2003; 2: 252–258.

Received: 2014.04.30